ArticleCancer management and research2025
Radiation-Induced Lymphopenia Prognosis and Risk Factors in Postmastectomy Radiotherapy Patients.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effects of radiation-induced lymphopenia (RIL) on survival in postmastectomy radiotherapy (RT) patients and identify relevant RIL predictive factors. Methods: Patients with breast cancer who received postmastectomy radiotherapy at the study hospital were enrolled over June 2016 to December 2022. The peripheral blood counts were obtained before and during treatment and at the first posttreatment follow-up. Lymphopenia was graded according to the degree of lymphocyte reduction. The Kaplan-Meier method was used to compare disease-free survival (DFS) and overall survival (OS) between grade 0-2 (G0-2) and grade 3 (G3) lymphopenia, and the Log rank test was used to compare between-group differences. DFS prognostic factors were determined through Cox regression analysis, and G3 lymphopenia predictive factors were assessed through logistic regression analysis. Results: 156 patients with a median RT duration of 5.0 weeks were enrolled. During treatment, 29 (18.6%), 36 (23.1%), 67 (42.9%), and 24 (15.4%) patients had G0, G1, G2, and G3 lymphopenia, respectively. Over RT duration, the absolute lymphocyte counts continued to decrease until they reached the nadir at week 5. The median follow-up duration was 45.5 months. The 1, 3-, and 5-year DFS rates were 97.0%, 90.3%, and 87.4% in the G0-2 group, respectively; they were higher than those in the G3 group (83.3%, 69.2%, and 39.5%, respectively; Conclusion: G3 RIL led to poor DFS in postmastectomy radiotherapy patients. BMI, RT modality, and heart and sternum exposure dose were noted to be independent RIL risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.